推进Src酶抑制:从结构设计到治疗创新 - 一个全面的审查
Yifeng Su1, Kun Zhu1, Jiahao Wang1
1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
European journal of medicinal chemistry
|February 14, 2025
概括
开发选择性Src酶抑制剂仍然是一个挑战. 最近药物设计方面的进展,包括人工智能和向蛋白质降解,显示出克服耐药性和提高治疗潜力的前景.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- Src 激酶是细胞信号传递的关键调节剂,对于瘤进展和治疗耐药性至关重要.
- 尽管进行了广泛的研究,但目前还没有获得临床批准的Src选择性激酶抑制剂,这凸显了开发方面的挑战.
研究的目的:
- 审查小分子Src抑制剂开发的最新进展.
- 分析实现Src异酶选择性和克服耐药性的新策略.
- 讨论加速抑制剂优化的新兴技术.
主要方法:
- 对结构设计策略和约束机制的审查.
- 基于片段的药物设计,全性向和共价抑制的分析.
- 整合人工智能,有机体平台和有针对性的蛋白质降解.
主要成果:
- 新兴的脚手架类通过创新的设计方法显示出希望.
- 利用非ATP结合口袋和共价抑制可以提高异酶的选择性.
- 人工智能和先进的平台加快了抑制剂优化和解决阻力.
结论:
- 理性设计原则和新兴技术对于下一代Src抑制剂至关重要.
- 克服选择性和非目标效应仍然是一个关键的挑战.
- 未来的开发重点是改善临床潜力和耐药性概况.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10.9K
11:11Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
7.1K
相关概念视频
Protein Kinases and Phosphatases
13.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
